NCT03263039View on ClinicalTrials.gov

Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab

PHASE2UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 21, 2017

Primary Completion Date

August 19, 2022

Study Completion Date

August 19, 2023

Conditions
Transitional Cell Carcinoma of the BladderBiomarkers
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg Q3W

Trial Locations (1)

Unknown

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Erasmus Medical Center

OTHER